# Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors

> **NCT00019630** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Childhood Soft Tissue Sarcoma
- Childhood Liver Cancer
- Bone Cancer
- Brain Tumor
- Kidney Tumor

## Interventions

- **DRUG:** doxorubicin HCl liposome

## Key facts

- **NCT ID:** NCT00019630
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-07
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2024-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00019630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00019630, "Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00019630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*